HUTCHMED announces positive Phase III results for sovleplenib in treating warm antibody autoimmune hemolytic anemia (wAIHA) in China. wAIHA is the most common form of AIHA, affecting 75-80% of adult cases. Results show rapid, durable hemoglobin responses with a favorable safety profile. The study met its primary endpoint, highlighting sovleplenib’s potential in managing this challenging condition. Further details will be presented at a scientific conference, with an NDA submission planned for the first half of 2026. Sovleplenib targets the spleen tyrosine kinase (Syk), showing promising results in wAIHA and immune thrombocytopenia (ITP). HUTCHMED is focused on developing targeted therapies for cancer and immunological diseases.

Read more at GlobeNewswire: HUTCHMED Announces Positive Topline Results of Phase III